Sanofi American Depositary Receipt (SNY)
Sanofi to Launch $1.20 Billion Share Buyback
The buyback comes as the French drugmaker said that its sales and earnings for the fourth quarter rose.
Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema
Sanofi said its amlitelimab drug confirmed its potential to treat eczema in patients 12 years and older in two late-phase studies.
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
Sanofi Says FDA Agrees to Review Diabetes Drug Age Range
The company said the regulator accepted a priority review to potentially expand the current age range for its Tzield type-1 diabetes drug to include children as young as one year old.
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
Sanofi to acquire Dynavax in $2.2B Deal to boost adult vaccines
French pharmaceutical giant Sanofi SA said on Wednesday it has agreed to acquire US-based vaccines company Dynavax Technologies Corp in a $2.2 billion deal, strengthening its presence in the adult immunization market. Under the agreement, Sanofi will launch a cash tender offer of $15.50 per Dynavax share, representing a 39% premium to the company's pre-deal stock price.
Sanofi to acquire US biotech Dynavax for $2.2 billion
French drugmaker Sanofi has entered into an agreement to acquire U.S. vaccines company Dynavax Technologies Corporation for around $2.2 billion (1.87 billion euros), it said on Wednesday.
Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal
The cash deal seeks to strengthen the French drugmaker's immunization portfolio after it suffered setbacks in clinical trials.
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi
South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to develop and sell the biotech company's experimental Alzheimer's disease treatment.
